In two phase 3, double-blind, 12-week studies (NCT03168334; NCT03168321), Tazarotene 0.045% polymeric emulsion lotion has demonstrated safety and efficacy in "Topical retinoids are a mainstay of acne treatment, though they are associated with..."

At week 12, tazarotene 0.045% lotion provided approximately 60% reductions in "The percentage of participants achieving treatment success and EGSS improvements..."

White adult participants had a mean age of 23.6 years, 79.1% were female, 71.0% "identified as non-Hispanic/Latino, and 89.6% had moderate EGSS at baseline..."

TEAE: 12.5% vs 2.5% (any TEAE; 31.2% vs 18.8%; related TEAE: 11.3% vs 1.1%)6

These results, combined with those from patients with skin of color (Black, Asian, Hispanic)7..."